Does ALIROCUMAB Cause Dyslipidaemia? 13 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Dyslipidaemia have been filed in association with ALIROCUMAB (Praluent). This represents 0.1% of all adverse event reports for ALIROCUMAB.
13
Reports of Dyslipidaemia with ALIROCUMAB
0.1%
of all ALIROCUMAB reports
0
Deaths
12
Hospitalizations
How Dangerous Is Dyslipidaemia From ALIROCUMAB?
Of the 13 reports, 12 (92.3%) required hospitalization, and 11 (84.6%) were considered life-threatening.
Is Dyslipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALIROCUMAB. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does ALIROCUMAB Cause?
Myalgia (1,571)
Product dose omission (1,354)
Injection site pain (1,220)
Muscle spasms (1,113)
Arthralgia (993)
Fatigue (922)
Pain (892)
Pain in extremity (888)
Product dose omission issue (864)
Injection site bruising (821)
What Other Drugs Cause Dyslipidaemia?
OLANZAPINE (230)
ROSUVASTATIN (206)
ARIPIPRAZOLE (185)
METHOTREXATE (175)
QUETIAPINE (161)
ATORVASTATIN (155)
RISPERIDONE (154)
METFORMIN (151)
TACROLIMUS (149)
ZIPRASIDONE (149)
Which ALIROCUMAB Alternatives Have Lower Dyslipidaemia Risk?
ALIROCUMAB vs ALISKIREN
ALIROCUMAB vs ALISKIREN HEMIFUMARATE
ALIROCUMAB vs ALISKIREN\HYDROCHLOROTHIAZIDE
ALIROCUMAB vs ALIZAPRIDE
ALIROCUMAB vs ALLANTOIN